Benchmark Initiates Coverage On Forward Air with Hold Rating
Benchmark analyst Christopher Kuhn initiates coverage on Forward Air (NASDAQ:FWRD) with a Hold rating.
Oppenheimer Initiates Coverage On Lumos Pharma with Outperform Rating, Announces Price Target of $20
Oppenheimer analyst Leland Gershell initiates coverage on Lumos Pharma (NASDAQ:LUMO) with a Outperform rating and announces Price Target of $20.
Stephens & Co. Initiates Coverage On Landec with Overweight Rating, Announces Price Target of $13
Stephens & Co. analyst Jacob Johnson initiates coverage on Landec (NASDAQ:LNDC) with a Overweight rating and announces Price Target of $13.
MKM Partners Initiates Coverage On Viper Energy Partners with Buy Rating, Announces Price Target of $31
MKM Partners analyst Leo Mariani initiates coverage on Viper Energy Partners (NASDAQ:VNOM) with a Buy rating and announces Price Target of $31.
JMP Is Bullish On This Cancer Stock “Sees New Way to Treat Cancer”
JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ:AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura…
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:APLS) with a Buy rating and a $75 price target. The analyst expects Apellis’s…
Craig-Hallum Initiates Coverage On Babcock & Wilcox with Buy Rating, Announces Price Target of $11
Craig-Hallum analyst Aaron Spychalla initiates coverage on Babcock & Wilcox (NYSE:BW) with a Buy rating and announces Price Target of $11.
Citigroup Assumes TELUS Intl at Buy, Raises Price Target to $33
Citigroup analyst Ryan Potter assumes TELUS Intl (NYSE:TIXT) with a Buy rating and raises Price Target to $33.
HC Wainwright Is Bullish On DICE Therapeutics – Read Why
H.C. Wainwright analyst Emily Bodnar initiated coverage on DICE Therapeutics Inc (NASDAQ:DICE) with a Buy rating and a price target of $40 (150%…
With Sustained Double-Digit Growth Profile, RBC Starts Coverage On This MedTech Stock
RBC Capital Markets initiated coverage on Penumbra Inc (NYSE:PEN) with an Outperform rating and a price target of $195 (59% implied upside).…